DexCom, Inc. $DXCM Stake Increased by World Investment Advisors

World Investment Advisors grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 34.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,089 shares of the medical device company’s stock after purchasing an additional 16,749 shares during the period. World Investment Advisors’ holdings in DexCom were worth $4,317,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of DXCM. CVA Family Office LLC lifted its holdings in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. ORG Partners LLC lifted its holdings in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares in the last quarter. Spire Wealth Management lifted its holdings in shares of DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 305 shares in the last quarter. Aventura Private Wealth LLC purchased a new stake in shares of DexCom in the fourth quarter valued at $43,000. Finally, Rothschild Investment LLC raised its holdings in shares of DexCom by 59.9% during the third quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock worth $44,000 after acquiring an additional 245 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the sale, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 4,412 shares of company stock worth $278,143. 0.28% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent research reports. BTIG Research reiterated a “buy” rating and set a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Sanford C. Bernstein set a $77.00 price objective on DexCom in a report on Friday, May 1st. TD Cowen cut their price objective on DexCom from $84.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 1st. Mizuho set a $75.00 price objective on DexCom in a report on Friday, May 1st. Finally, Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $83.22.

DexCom Price Performance

NASDAQ DXCM opened at $57.82 on Friday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The stock’s 50-day moving average is $63.69 and its two-hundred day moving average is $65.92. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a market cap of $22.31 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 1.01 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business’s revenue was up 15.0% compared to the same quarter last year. During the same period last year, the company earned $0.32 earnings per share. On average, analysts anticipate that DexCom, Inc. will post 2.56 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.